IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C

blonca9
Jan 22
1 min read

President and CEO Professor Mallory Factor KCNG describes the mechanism of the therapy and the company's commercial launch and hiring. Plus,how IntraBio hopes to develop this for other broader indications in the future, such as Parkinson's disease.

Recent Posts

See All

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs

Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries

Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases

IntraBio, which moved from Oxford, UK to Austin, Texas last year, received FDA approval in September for its modified amino acid, AQNEURSA, to treat neurological manifestations of Niemann-Pick type C

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight